Levosimendan and Alternation Performance in TauP301L-BiFC Mice
Animal study · TauP301L-BiFC mice; n = 11 per group [1]
TauP301L-BiFC mice received Levosimendan intraperitoneally. Treated mice showed higher percent alternation than the vehicle-treated group.
| Endpoint | Reported result | Reference |
|---|---|---|
| percent alternation | percent alternation 70.4 ± 4.2% | [1] |
Conditions shared by the study groups
- Route
- intraperitoneally
- Treatment course
- from 9 months of age for 4 months, three times a week
- Vehicle
- PBS containing 40% polyethylene glycol (PEG; Sigma)
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Levosimendan 5 mg/kg | vehicle-treated group | 5 mg/kg from 9 months of age for 4 months, three times a week: 70.4 ± 4.2%, p < 0.05 compared with the vehicle-treated group (52.8 ± 2.6%, p < 0.01 compared to WT). | [1] |
- Levosimendan 5 mg/kg
- Model: TauP301L-BiFC mice; n = 11 per group
Methods and source locations
Compound reported in the paper: Levosimendan
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animal studies > Drug administration to TauP301L-BiFC mice (S73, S74); Results > Levosimendan rescues cognitive deficits and tau pathology in TauP301L-BiFC mice (S352, S353, S361)
percent alternation: percent alternation; comparator: vehicle-treated group — Results > Levosimendan rescues cognitive deficits and tau pathology in TauP301L-BiFC mice (S352, S353, S361)
Levosimendan 5 mg/kg · Results > Levosimendan rescues cognitive deficits and tau pathology in TauP301L-BiFC mice (S353, S361)